Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson’s disease
Figure 24.1 Phases of development for a surrogate marker of progression in Parkinson’s disease (PD). Biomarker discovery leads to identification of species that are most often first studied in cross-sectional…